Potent polo-like kinase 1 (PLK1) inhibitor

Novel ATM inhibitor with cancer cell specific radiosensitization activity

Novel, soluble, permeable, and selective BRD7/9 inhibitor

Novel PCAF/GCN5 degrader, modulating PCAF/GCN5 immune cell function through a PROTAC approach

Negative control for GSK699

Novel stabilizer of Zα 1 -antitrypsin, blocking Zα 1 -antitrypsin polymerisation in vitro, reducing intracellular polymerisation and increasing the secretion of Zα 1 -antitrypsin threefold in an iPSC model of disease

Novel potent inhibitor of EchA6

Novel Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor

Negative control for GSK789

Novel potent and selective BET pan-BD2 inhibitor

Novel agonist of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2)

Selective glucocorticoid receptor agonist (SEGRA)

Negative control for GSK8814

Highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitor

Antimalarial

Negative control for GSK073

Novel potent protein kinase C-related kinase 1 (PRK1) inhibitor with IC50 of 40±8.7 nM)

Novel potent inhibitor of bacterial type IIA topoisomerases

Selective inhibitor of iE-DAP-stimulated IL-8 release via the NOD1 signaling pathway

Potent inhibitor of bacterial type IIA topoisomerases

Novel potent transrepression-selective liver X receptor modulator with anti-inflammatory activity

Negative control as an inactive IDH1 inhibitor